Director, Global Compliance Monitoring and ABAC Programs

Overview The Director, Global Compliance Monitoring and Anti-Bribery/Anti-Corruption (ABAC) Programs, will report to the Vice President of Global Compliance Operations, Programs & Monitoring (VP GCO), and is responsible for the design, implementation, oversight, and continuous improvement of compliance systems, tools, processes, and programs designed to identify and mitigate ABAC risk, drive operational efficiency, and enhance the effectiveness of the Global Compliance program and the broader enterprise. The Director will be responsible for helping advance Alnylam’s Global Compliance Program and enterprise efficiencies by partnering cross-functionally with senior leadership in Internal Audit, Finance, IT, and Legal to design compliance tools and systems within an end-to-end procure-to-pay process, to optimize end-user experience. The Director will coordinate across the E&C organization, collaborate with key business stakeholders across the Company, and present to senior leadership. The Director must possess a strategic, innovative mindset and must take a practical, solutions-oriented approach to (1) leveraging technology to evolve, harmonize, streamline, and strengthen the Global Compliance program and the broader enterprise procure-to-pay process; (2) supporting Compliance business partners in carrying out their advisory responsibilities; and (2) enabling end-users in the broader business to conduct their daily work in a compliant fashion. Key Responsibilities · Designing and delivering a global risk assessment program that assesses the company’s compliance risk profile and associated risk mitigation efforts, with related processes and reporting to engage senior leadership and inform into other elements of the Global Compliance program, such as monitoring, training, and policy development · Designing compliance review and approval tools with embedded compliance controls to strengthen adherence while taking into account end user experience, in such areas as conflicts of interest, external funding, healthcare professional, healthcare organization, and patient engagements and interactions, and other transfers of value, to strengthen the ABAC risk mitigation, and developing and implementing relevant training and resources for the business · Launching a global monitoring and data analytics program that leverages technology to collect robust and standardized data from multiple sources to produce meaningful, dynamic, and actionable reports and dashboards with insights for both Compliance professionals and business leaders on potential outliers and trends, to support internal audits, and to inform into other elements of the Global Compliance program, such as investigations, risk assessment, training and policy development · Drafting concise and accurate reports, including executive-level summaries of output from risk assessments, monitoring, and data analytics, and presentations providing an overview of the key issues, findings, trends, outcomes, and necessary remediation, including presentation to senior leadership at various forums (e.g., regular updates to Legal, HR, and Internal Audit, Compliance Committees, Board meetings, as necessary) · Supporting the CECO and E&C Leadership Team with periodic updates of monitoring and ABAC programs · Partnering with cross-functional leaders in Strategic Sourcing, Legal, Internal Audit, and providing strategic guidance to identify, design, implement, and refine compliance-related tools, platforms, and systems for HCP Engagements, External Funding, Transfers of Value, and Third Party Risk Management, Contracting, and Payment, within an integrated enterprise-wide procure-to-pay process, to embed compliance principles and address ABAC and other key ethics & compliance risks and to enhance enterprise efficiencies and improve end-user experience Qualifications · 10 years’ experience with increasing responsibility in compliance, audit, or legal roles; focus on operations in the pharmaceutical or life science industry, including presenting to senior leadership, is strongly preferred · Demonstrated ability to collaborate and influence cross-functionally with US and ex-US personnel. · Direct experience in leading teams responsible for designing, implementing, overseeing, and improving compliance systems and tools; risk assessments; data analytics and monitoring; and third party risk management processes; · Knowledge of laws and regulations applicable to global pharmaceutical companies, including, the U.S. Foreign Corrupt Practices Act, US fraud and abuse and false claims laws, and industry codes on interactions with healthcare professionals · Possess a strategic, innovative mindset and must take a practical, solutions-oriented approach · Strong commitment to ethics and integrity in all aspects of their work · Must be able to work and lead collaboratively in a team environment with a wide variety of company personnel on a broad range of matters, including Compliance, Legal, Finance, and business colleagues, as well as physicians, scientists, and individuals of different nationalities, and engage in intellectual debate with expertise areas; · Ability to manage multiple tasks simultaneously, to work independently and manage discrete areas of responsibility with limited supervision, and to flourish in a fast-paced environment; · Able to thrive in a proactive ethical culture in which compliance and business objectives are mutually reinforcing; strong motivation and ability to champion a comprehensive compliance program that is integrated well with Alnylam’s business and culture · Excellent organizational and time management skills, refined communication skills (verbal and written) with fluency in written and spoken English required, including the ability to communicate persuasively throughout all layers of an organization · Travel will be required on occasion to Alnylam offices in the U.S. and overseas About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.

Salary : $139,000 - $176,000